IGC Pharma is a clinical stage pharmaceutical company that is dedicated to improving the health and well-being of women and their families. Through the discovery and development of innovative therapies, they aim to tackle conditions such as Alzheimer's disease, premenstrual syndrome (PMS), dysmenorrhea, and sleep disorders. Formerly known as India Globalization Capital, Inc., IGC Pharma was incorporated in Maryland in 2005.

Their revenue currently stems from women's wellness products, but their focus is shifting towards investigational drugs for Alzheimer's disease. In fact, they have entered Phase 2 with IGC-AD1, which has shown efficacy in reducing neuropsychiatric symptoms associated with dementia and Alzheimer's. Additionally, IGC Pharma has acquired a molecule called TGR-63, which demonstrates an affinity for reducing neurotoxicity in Alzheimer's cell lines.

Committed to scientific excellence, patient-centeredness, and collaboration, they strive to advance the understanding and treatment of these conditions while addressing the unique health needs of women across their lifespan. Furthermore, IGC Pharma aims to develop effective therapies for PMS and dysmenorrhea, alleviating symptoms and improving the quality of life for those affected. By bringing innovative therapies to the market, they hope to enhance the lives of millions of individuals impacted by Alzheimer's disease, PMS, dysmenorrhea, and sleep disorders